ID: ALA3314193

Max Phase: Preclinical

Molecular Formula: C26H15BrCl2N4O2S

Molecular Weight: 598.31

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1N=C(N2N=C(c3ccc(Cl)cc3)CC2c2ccc(Cl)cc2)S/C1=C1\C(=O)Nc2ccc(Br)cc21

Standard InChI:  InChI=1S/C26H15BrCl2N4O2S/c27-15-5-10-19-18(11-15)22(24(34)30-19)23-25(35)31-26(36-23)33-21(14-3-8-17(29)9-4-14)12-20(32-33)13-1-6-16(28)7-2-13/h1-11,21H,12H2,(H,30,34)/b23-22-

Standard InChI Key:  HHJZHLLDRXPANZ-FCQUAONHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 598.31

Molecular Weight (Monoisotopic): 595.9476

AlogP: 6.90

#Rotatable Bonds: 2

Polar Surface Area: 74.13

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.00

CX Basic pKa: 0.92

CX LogP: 6.27

CX LogD: 6.27

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.33

Np Likeness Score: -1.14

References

1. Avdieiev S, Gera L, Havrylyuk D, Hodges RS, Lesyk R, Ribrag V, Vassetzky Y, Kavsan V..  (2014)  Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds.,  22  (15): [PMID:25012567] [10.1016/j.bmc.2014.06.046]

Source

Source(1):

• Scientific Literature